Log in

Relevant bibliographies by topics / OSU-2S

Contents

Journal articles
Dissertations / Theses
Conference papers

Academic literature on the topic 'OSU-2S'

Author: Grafiati

Published: 4 June 2021

Last updated: 13 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'OSU-2S.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "OSU-2S"

1

Goswami, Swagata, Chi-Ling Chiang, Kevan Zapolnik, et al. "ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL." Blood 134, Supplement_1 (2019): 3798. http://dx.doi.org/10.1182/blood-2019-128828.

Full text

Abstract:

The receptor tyrosine kinase ROR1 is uniquely expressed on and required for many hematological malignancies such as t(1;19) positive acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL). The t(1;19) is one of the most frequent translocations in B-ALL, observed in both adult and pediatric patients. The translocation has intermediate prognosis on its own, but is associated with a poor prognosis in the unbalanced der(19)t(1;19) form in pediatric ALL, and in the context of hyperdiploid B-ALL. While leukemic cell dependence on ROR1 is known, ROR1 lacks kinase activity making it

APA, Harvard, Vancouver, ISO, and other styles

2

Goswami, Swagata, Rajeswaran Mani, Chi-Ling Chiang, et al. "CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia." Blood 128, no. 22 (2016): 2748. http://dx.doi.org/10.1182/blood.v128.22.2748.2748.

Full text

Abstract:

Abstract Acute myeloid leukemia (AML) is an incurable disease with 5 year survival rates of 10% in patients over 60 years. Poor tolerance to chemotherapy, chemo resistance and high rate of relapse warrants less toxic and more effective regimens in AML. OSU-2S is a novel non-immunosuppressive derivative of FTY720, a sphingosine analogue. The promising in-vitro and in-vivo activity of OSU-2S against a number of leukemias and lymphomas, and other malignancies such as hepatocellular carcinoma, impelled us to evaluate the activity of OSU-2S in AML. The potent cytotoxic activity of the OSU-2S (5µM,

APA, Harvard, Vancouver, ISO, and other styles

3

Mohamed Khalil, Sohaila, Swagata Goswami, Xiaokui Mo, and Natarajan Muthusamy. "Protein Phosphatase 2A Activation Dependent Down Regulation of PGC1-Alpha and FOXO1 Phosphorylation with OSU-2S in Human Lymphoma Cells." Blood 134, Supplement_1 (2019): 3977. http://dx.doi.org/10.1182/blood-2019-129224.

Full text

Abstract:

Metabolic reprogramming has been recognized to provide survival advantage in cancer cells. Protein phosphatase 2A (PP2A) is a serine/threonine phosphatase that is involved in regulation of multiple cellular pathways including metabolic events. OSU-2S, is a novel PP2A activator that exhibited potent anti-cancerous properties against human and canine lymphoma cell lines and primary human and canine lymphoma patient samples. It has been shown to activate PP2A in Ramos human lymphoma cell line leading to cytotoxicity that is prevented by inhibition of PP2A with okadaic acid (OA). Peroxisome prolif

APA, Harvard, Vancouver, ISO, and other styles

4

Mani, Rajeswaran, Frank W. Frissora, Ching-Shih Chen, John C. Byrd, and Natarajan Muthusamy. "OSU-2S, A Novel FTY720 derivative, Mediates Cytotoxicity In Chronic Lymphocytic Leukemia Through PKC Dependent Modulation of SHP1 Tyrosine Phosphatase." Blood 118, no. 21 (2011): 2499. http://dx.doi.org/10.1182/blood.v118.21.2499.2499.

Full text

Abstract:

Abstract Abstract 2499 Despite development of numerous chemotherapeutic agents against Chronic Lymphocytic Leukemia (CLL), drug resistance remains impediment in the successful treatment of CLL. Currently several kinases including SYK, BTK, Pim and PI3K are being targeted with inhibitors for therapy in CLL. However, no phosphatase activation directed therapeutics has been described for CLL. We have recently reported FTY720, a potent immunosuppressive agent derived from fungal sphingosine analog ISP-1 to exhibit potent in-vitro and in-vivo preclinical activity against CLL and Mantle cell Lymphom

APA, Harvard, Vancouver, ISO, and other styles

5

Mani, Rajeswaran, Yicheng Mao, Frank W. Frissora, et al. "Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia." Blood 122, no. 21 (2013): 4168. http://dx.doi.org/10.1182/blood.v122.21.4168.4168.

Full text

Abstract:

Abstract The discovery of predominantly inactive phosphatases in a variety of cancers and the potential for phosphatase targeted therapy as an alternative to kinase inhibitors especially in situations where the efficacy of the kinase inhibitors are compromised due to resistance mechanisms attributed to mutations and single nucleotide polymorphisms of the drug targets prompted us to evaluate potential activators of phosphatases in chronic lymphocytic leukemia (CLL) and other B cell malignancies. We have recently identified cytotoxic activity of OSU-2S, a novel non-immunosuppressive FTY720 deriv

APA, Harvard, Vancouver, ISO, and other styles

6

Walker, Christopher, Joshua J. Oaks, Paolo Neviani, et al. "PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives." Blood 116, no. 21 (2010): 2901. http://dx.doi.org/10.1182/blood.v116.21.2901.2901.

Full text

Abstract:

Abstract Abstract 2901 FTY720 is a sphingosine analog proposed by the FDA for treating Multiple Sclerosis patients because of its immunosuppressive activity, which depends on its ability to prevent lymphocyte egress into the peripheral blood. To act as an immunosuppressive drug, FTY720 undergoes sphingosine kinase 2 (SPHK2) phosphorylation and internalization upon interaction with the sphingosine-1-phosphate receptor 1 (S1PR1). FTY720 also acts as a potent activator of protein phosphatase 2A (PP2A), a tumor suppressor found inactivated in chronic and blast crisis CML with wild type or imatinib

APA, Harvard, Vancouver, ISO, and other styles

7

Oaks, Joshua J., Ramasamy Santhanam, Christopher J. Walker, et al. "Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies." Blood 122, no. 11 (2013): 1923–34. http://dx.doi.org/10.1182/blood-2013-03-492181.

Full text

Abstract:

Key Points The tumor suppressor PP2A is repressed in Jak2V617F-driven myleoproliferative neoplasms by a Jak2/PI3K/PKC/SET signaling pathway. PP2A-activating (eg, FTY720, OSU-2S) but not sphingosine-1-phosphate agonistic (eg, FTY720-P) drugs selectively kill Jak2V617F+ cells.

APA, Harvard, Vancouver, ISO, and other styles

8

Omar, Hany A., Chih-Chien Chou, Lisa D. Berman-Booty, et al. "Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma." Hepatology 53, no. 6 (2011): 1943–58. http://dx.doi.org/10.1002/hep.24293.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Mani, R., R. Yan, X. Mo, et al. "Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma." Veterinary and Comparative Oncology 15, no. 3 (2016): 1115–18. http://dx.doi.org/10.1111/vco.12221.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Mao, Yicheng, Jiang Wang, Yuan Zhao, et al. "Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography–tandem mass spectrometry." Journal of Pharmaceutical and Biomedical Analysis 98 (September 2014): 160–65. http://dx.doi.org/10.1016/j.jpba.2014.05.022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "OSU-2S"

1

Mani, Rajeswaran. "Preclinical development of a non-immunosuppressive FTY720 derivative OSU-2S forchronic lymphocytic leukemia and other B-cell malignancies." The Ohio State University, 2014. http://rave.ohiolink.edu/etdc/view?acc_num=osu1404067069.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Omar, Hany Ahmed Mostafa Mohamed. "Molecular Pharmacology and Preclinical Studies of Novel Small-molecule Targeted Agents for The Treatment of Hepatocellular Carcinoma." The Ohio State University, 2010. http://rave.ohiolink.edu/etdc/view?acc_num=osu1290565602.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Lin, Zi-Yin, and 林姿吟. "OSU-2S induces apoptosis and autophagy in human oral squamous cell carcinoma." Thesis, 2015. http://ndltd.ncl.edu.tw/handle/av4djt.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "OSU-2S"

1

Omar, Hany A., Mai F. Tolba, Jui-Hsiang Hung, and Taleb H. Al-Tel. "Abstract A23: Novel approach for targeting hepatocellular carcinoma cell survival: OSU-2S/Sorafenib combination." In Abstracts: AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1557-3265.pmccavuln16-a23.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Mani, Rajeswaran, Chi-Ling Chiang, Frank W. Frissora, et al. "Abstract 4406: ROR1 targeted delivery of OSU-2S, a non-immunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle cell lymphomain-vitroandin-vivo." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4406.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!